Specification
Description
KDM4B-IN-B3, also know as NCGC00244536, is a novel KDM4 inhibitor. KDM4B-IN-B3 inhibits the in vivo growth of tumors derived from PC3 cells and ex vivo human PCa explants. Histone lysine demethylase KDM4/JMJD2s are overexpressed in many human tumors including prostate cancer (PCa).
Synonyms
KDM4B-IN-B3; KDM4B IN B3; KDM4BINB3; NCGC00244536; NCGC-00244536; NCGC 00244536
IUPAC Name
3-(8-Hydroxyquinolin-6-yl)-N-(3-phenylpropyl)benzamide
Canonical SMILES
O=C(NCCCC1=CC=CC=C1)C2=CC=CC(C3=CC(O)=C4N=CC=CC4=C3)=C2
InChI
InChI=1S/C25H22N2O2/c28-23-17-22(16-20-12-6-13-26-24(20)23)19-10-4-11-21(15-19)25(29)27-14-5-9-18-7-2-1-3-8-18/h1-4,6-8,10-13,15-17,28H,5,9,14H2,(H,27,29)
InChI Key
NYKBXXGHEMXSBB-UHFFFAOYSA-N
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Storage
Dry, dark and at 0-4 °C for short term (days to weeks) or -20 °C for long term (months to years).
Biological Target
NCGC00244536 is a potent KDM4B inhibitor with an IC50 of 10 nM.
Drug Formulation
This drug may be formulated in DMSO
Elemental Analysis
C, 78.51; H, 5.80; N, 7.32; O, 8.37
HS Tariff Code
2934.99.9001
In Vitro Activity
This study tested the effect of these compounds on the growth of LNCaP cells (Fig. S1A) and selected NCGC00247751 (A1), NCGC00244536 (B3), and NCGC00247743 (I9), which inhibited LNCaP cell growth with IC50s in the μM range (Fig. 1A). These inhibitors suppressed the catalytic activity of KDM4B effectively and among them B3 was the most potent, with an IC50 of ca. 10 nM (Fig. 1B).
Reference: Chem Biol. 2015 Sep 17;22(9):1185-96. https://pubmed.ncbi.nlm.nih.gov/26364928/
Shipping
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Stock Solution Storage
0-4 °C for short term (days to weeks), or -20 °C for long term (months).